Gilead to buy Menlo Park biotech for 6 times its 2018 IPO value
March 02, 2020 at 10:15 AM EST
The company that Foster City-based Gilead is buying has an investigational lead product candidate, magrolimab, that is in clinical development as a potential treatment of several cancers. it also has two other experimental medicines that may soon enter clinical tests.
